Vertex Pharmaceuticals Inc annual net income for fiscal TTM was $4.3 billion, an increase of 9.7% from $4.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Net Income (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $4.3B | $4.0B | ($536M) | $3.6B | $3.3B | $2.3B | $2.7B | $1.2B | $2.1B | $263M | ($112M) | ($558M) | ($739M) | ($445M) | ($107M) | $30M | ($755M) | ($642M) | ($460M) | ($391M) | ($207M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Net Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $1.0B | $1.2B | $1.1B | $1.0B | $646M | $913M | $1.0B | ($3.6B) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More VRTX metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All VRTX financial statements → Interactive VRTX charts →
About TickerBase · Data methodology & sources